InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Immuneering Corp

IMRX Clue Score35
United States Fiscal year ends December CIK 0001790340
$3.86 -2.03% Close, 12 Oct 2026
Alert on the numbers Alert on insider trades
Price $3.86 −82.23% Close, 12 Oct 2026

Closing prices at the end of each trading day, from 30 Jul 2021. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2020Revenue2.3Operating income−17.1Net income−17.0EPS, diluted−3.44Fiscal year 2021Revenue2.1 −10.0%Operating income−33.9Net income−33.5EPS, diluted−2.46Fiscal year 2022Revenue0.3 −84.8%Operating income−51.7Net income−50.5EPS, diluted−1.91Fiscal year 2023Revenue0.0 −100.0%Operating income−58.4Net income−53.5EPS, diluted−1.88Fiscal year 2024Operating income−64.1Net income−61.0EPS, diluted−2.04Fiscal year 2025Operating income−59.4Net income−56.0EPS, diluted−1.27
FY2020FY2021FY2022FY2023FY2024FY2025
Revenue 2.3 2.1 0.3 0.0 n/a n/a
Growth −10.0% −84.8% −100.0%
Operating income −17.1 −33.9 −51.7 −58.4 −64.1 −59.4
Net income −17.0 −33.5 −50.5 −53.5 −61.0 −56.0
Growth
EPS, diluted −3.44 −2.46 −1.91 −1.88 −2.04 −1.27

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Gross marginOperating marginNet margin
Fiscal year 2020Gross margin44.6%Operating margin−739.0%Net margin−737.2%Free cash flow margin−634.8%Fiscal year 2021Gross margin44.6%Operating margin−1,629.2%Net margin−1,612.3%Free cash flow margin−1,486.2%Fiscal year 2022Gross margin50.1%Operating margin−16,325.8%Net margin−15,937.3%Free cash flow margin−14,148.4%Fiscal year 2023Fiscal year 2024Fiscal year 2025
FY2020FY2021FY2022FY2023FY2024FY2025
Gross margin 44.6% 44.6% 50.1% n/a n/a n/a
Operating margin −739.0% −1,629.2% −16,325.8% n/a n/a n/a
Net margin −737.2% −1,612.3% −15,937.3% n/a n/a n/a
Free cash flow margin −634.8% −1,486.2% −14,148.4% n/a n/a n/a

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2020Operating cash flow−14.6Capital expenditure−0.1Free cash flow−14.7Fiscal year 2021Operating cash flow−30.9Capital expenditure−0.1Free cash flow−30.9Fiscal year 2022Operating cash flow−44.1Capital expenditure−0.7Free cash flow−44.8Fiscal year 2023Operating cash flow−49.0Capital expenditure−0.3Free cash flow−49.3Fiscal year 2024Operating cash flow−55.0Capital expenditure−0.1Free cash flow−55.1Fiscal year 2025Operating cash flow−45.3Capital expenditure−0.1Free cash flow−45.5
FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −14.6 −30.9 −44.1 −49.0 −55.0 −45.3
Capital expenditure −0.1 −0.1 −0.7 −0.3 −0.1 −0.1
Free cash flow −14.7 −30.9 −44.8 −49.3 −55.1 −45.5
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2020Cash37.1Shareholders’ equity−22.5Fiscal year 2021Cash74.9Shareholders’ equity156.0Fiscal year 2022Cash72.6Shareholders’ equity109.9Fiscal year 2023Cash59.4Shareholders’ equity90.6Fiscal year 2024Cash36.1Shareholders’ equity41.4Fiscal year 2025Cash128.6Shareholders’ equity218.5
FY2020FY2021FY2022FY2023FY2024FY2025
Cash 37.1 74.9 72.6 59.4 36.1 128.6
Shareholders’ equity −22.5 156.0 109.9 90.6 41.4 218.5

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Balance sheet

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2020 31 Dec 2020 FY2021 31 Dec 2021 FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Assets
37.1 74.9 72.6 59.4 36.1 128.6
0.5 0.2 0.0 0.0 n/a n/a
0.1 0.8 1.4 1.4 1.1 0.9
n/a 6.7 6.7 6.7 6.7 6.7
38.4 166.7 122.4 102.6 52.7 232.0
Growth +333.9% −26.6% −16.2% −48.6% +340.1%
Liabilities
2.8 10.7 12.5 12.0 11.3 13.5
Equity
−25.7 −59.3 −109.8 −163.3 −224.3 −280.3
−22.5 156.0 109.9 90.6 41.4 218.5
Growth −29.6% −17.5% −54.3% +427.9%